Cassava Sciences continues to develop simufilam, its lead small molecule therapeutic targeting filamin A in tuberous sclerosis complex (TSC)-related epilepsy. The company's recent quarterly filing reveals stable risk factors with an emphasis on regulatory compliance and manufacturing dependencies. Despite litigation settlements weighing on the company, Cassava maintains a cash position supporting ongoing R&D. Key growth drivers include clinical trial advancements and exploration of new indications, while risks persist from legal exposures, single-source supply reliance, and competitive pressures in CNS drug development.